|  |
| --- |
| **Supplemental Table 2.** Effect of CE/BZA on Serum Adipokines and Systemic Inflammation*1* |
|  | **Post-Treatment Outcomes** | **P-value** |
| **Placebo** | **CE/BZA** |
| Adiponectin, ug/mL | 7.63 ± 2.81 | 7.81 ± 2.17 | 0.62 |
| C-reactive protein (CRP), mg/L | 2.04 ± 0.89 | 2.58 ± 1.27 | 0.33 |
| Fibroblast growth factor 21 (FGF21), pg/mL | 391.44 ± 348.46 | 317.88 ± 156.98 | 0.53 |
| Gla-type osteocalcin (Gla-OC), ng/mL | 7.91 ± 2.64 | 8.07 ± 2.81 | 0.87 |
| Glu-type osteocalcin (Glu-OC), ng/mL | 4.87 ± 1.94 | 6.28 ± 3.63 | 0.28 |
| Glu/Gla Ratio | 0.64 ± 0.24 | 0.81 ± 0.41 | 0.30 |
| Intact osteocalcin (Intact-OC), ng/mL | 4.97 ± 2.13 | 5.13 ± 1.87 | 0.88 |
| Lipocalin 2 (LCN2), ng/mL | 13.31 ± 13.56 | 10.76 ± 9.57 | 0.24 |
| Leptin, ng/mL | 50.00 ± 8.93 | 50.44 ± 11.71 | 0.91 |
| Plasminogen activator inhibitor-1 (PAI-1), ng/mL | 23.17 ± 10.48 | 23.63 ± 10.60 | 0.88 |
| Retinol-binding protein 4 (RBP4), ug/mL | 23.42 ± 11.80 | 23.96 ± 12.04 | 0.81 |
| Thiobarbituric acid reactive substances (TBARS), nmol/mL | 7.65 ± 2.62 | 6.92 ± 2.01 | 0.45 |

*Abbreviations: CE/BZA, conjugated estrogens/bazedoxifene;*

*1Estimates of means (±SD) are listed for all post-treatment outcome. P-values denote treatment-differences following adjustment for crossover design (treatment, order of treatment).*